© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Fexofenadine Hydrochloride didn’t appear out of nothing. Its story ties back to older antihistamines and the steady push to move beyond drowsy side effects. Terfenadine once held the stage before fexofenadine took over, offering similar relief for allergies without some of the cardiac concerns linked to its predecessor. This transition mattered because it reflected a clear demand from both doctors and patients: relief from symptoms without sacrificing daily function. The development also highlighted a shift—chemists had to dig deep to untangle the balances between efficacy, safety, and market needs, finally landing on fexofenadine as a go-to for those seeking a non-sedating option. Over time, its reference standard became essential for guaranteeing consistent quality in both research and production worldwide.
A reference standard isn’t just a technical checkpoint. In practical terms, it sets the benchmark for pharmaceutical labs to measure every batch against, making sure each tablet does what the box promises. In regulated markets, cutting corners on reference materials creates unnecessary risks. Without a solid benchmark, labs can’t confidently compare samples or troubleshoot issues in production. Researchers rely on this material to validate assays, and each new lot gets measured against this original. Over the years, I’ve watched teams pore over logbooks, checking purity and identity through high-performance liquid chromatography or nuclear magnetic resonance, all because they trust the reference material shines a clear light on what’s acceptable.
Fexofenadine Hydrochloride doesn’t masquerade as something it’s not. Most days in a lab, it looks like a white or off-white powder—nothing flashy, just functional. Its chemical formula (C32H39NO4∙HCl) gives a clue to its complexity. It dissolves better in water than in organic solvents, which helps when prepping lab solutions or developing oral formulations. Melting points and spectral data often back up the material’s identity, especially when labs guard against traces of impurities that might blur test results. Solid stability is key; with the right storage conditions, the reference standard keeps its integrity for long stretches, a boon for any research timeline.
If you’ve ever worked with pharmaceutical reference materials, the importance of clear labeling can’t be overstated. Each vial or container tells a story—source, storage guidance, expiration, and lot number. These details give traceability, often overlooked until someone needs to retrace a batch’s history. Purity usually sits above 99 percent, with water content, residual solvents, and microbial data filling out the rest of the picture. It’s not just a matter of regulatory compliance; it builds trust across research and industry partners. Mislabeling here can stall studies or even trigger regulatory headaches, something every quality control analyst learns the hard way.
Synthesizing a batch for consistent use doesn’t come easy. Starting with the correct precursor, chemists move through carefully controlled reactions, usually involving ester hydrolysis and salt formation steps. Each phase—reaction, purification, drying—gives another shot for things to go wrong, so labs use validated protocols, always checking the final product with analytic tools like mass spectrometry and infrared spectroscopy. Teams learn to calibrate instruments often, knowing a sloppy approach brings down not just one experiment, but everything that depends on reliable reference material. I’ve seen projects halted for weeks just because a standard failed its purity check or someone skipped a critical re-assay.
In its standard form, fexofenadine hydrochloride shows stability that suits its role as an antihistamine. Some research dives into derivatives, particularly to understand metabolic breakdown in the human body or to chase new analogs for better therapeutic profiles. This interest doesn’t stem from idle curiosity; tweaking the structure can lead to compounds with longer activity or fewer side effects. Each modification skirts the line between innovation and safety, especially as teams must continuously prove that these changes don’t bring new, hidden dangers.
Anyone searching chemical databases knows the power of names. Fexofenadine hydrochloride travels under various aliases, from its CAS registry number to short forms like Allegra’s parent compound. These synonyms bridge gaps between research articles, regulatory submissions, and supply chain paperwork. Confusion over names or spellings spawns mistakes, with stories circulating of samples being ordered in the wrong form or delays arising because paperwork doesn’t match. Clarity in naming may sound trivial, but it keeps costly errors off the table and smooths collaboration in multinational studies.
Respect for safety is more than lab coat deep. Reference materials need strict handling—not because fexofenadine is especially hazardous, but because any lapse opens the door to contamination, wasted resources, or, in extreme cases, lab injuries. Labs track each gram, store it in locked cabinets, and document every withdrawal. Some workers may develop sensitivities with repeated exposure, though most incidents relate to poor storage or cross-contamination. Routine training helps anchor good habits, while regulatory guidelines set boundaries no one ignores for long without consequences.
Most recognize fexofenadine as an allergy remedy, yet its reference standard does far more behind the scenes. Quality control labs run daily checks to verify finished tablets, capsules, and even research formulations meet tight specs. Bioanalytical research turns to it when measuring how much of the compound appears in blood samples during clinical trials. New applications pop up every so often, touching areas like post-surgical inflammation or off-label use in chronic urticaria when cheaper alternatives run afoul of regulatory snags. This versatility helps keep the reference standard relevant long after initial approval.
Pharmaceutical R&D leans heavily on reference materials to manage both replication and innovation. Every phase, from drug metabolism studies to long-term stability trials, depends on the assumed accuracy of standard samples. Teams must synchronize across continents, knowing a reference’s purity and identity checks fuel everything from early screenings to the last audit before a product launch. In my experience, research grinds to a halt when shipments are delayed or batch variations creep in. Every year, labs debate sourcing from official pharmacopoeia agencies or private suppliers, always weighing cost, paperwork, and speed.
Toxicity data on fexofenadine comes from rigorous animal and clinical testing. Researchers pressed for higher doses in the early days, looking for red flags around the heart, liver, and kidney. Fexofenadine stood out, showing a favorable margin between therapeutic and harmful levels—a relief for both regulators and patients given the issues with terfenadine. Long-term use studies haven’t revealed major concerns, yet researchers keep a watchful eye. Occupational exposure risks remain low, but labs stress the importance of hygiene, not because the risk is high, but to avoid unknowns or accidental mix-ups that could cloud experimental results.
Science rarely sits still. Even as fexofenadine enjoys broad approval and generic status, the reference standard faces steady demand. Analytical methods evolve—techniques like UHPLC and LC-MS demand cleaner, better-characterized standards. At the same time, global harmonization efforts press for tighter specs and documentation. There’s also interest in how fexofenadine and its reference standard can support new drug delivery systems or combination therapies. I’ve seen collaborations form between industry and academia looking for novel uses or improved bioavailability. Success here depends on quality standards keeping pace with innovation, with clear communication and supply chain resilience serving as old but necessary pillars.
Anyone who has taken an allergy tablet—especially those little pink or white ones—has probably put their trust in fexofenadine hydrochloride, even if unknowingly. Before any allergy pill lands in a pharmacy or on a store shelf, it goes through layers of testing and quality control. This is where reference standards come into play. Fexofenadine hydrochloride reference standard is not just a chemical—it serves as the gold measure for scientists and pharmacists making and checking antihistamine medications.
A reference standard acts like a ruler in the world of medicine manufacturing. If the dose in an allergy medication says 120 mg fexofenadine, that claim relies on comparison to the reference standard. Labs use this standard to see if what’s in the tablet really matches what’s on the label. Without this, patients have no assurance the medicine they take will work as expected.
Anyone who deals with pollen, pet dander, or mold knows relief from symptoms changes daily life. Fexofenadine hydrochloride became the go-to for many allergies because it calms histamine response without making most users sleepy. This makes it safe for drivers, workers, and students. In drug labs, the reference standard is the purest form of this compound, verified and measured precisely. Doctors count on these exact figures because dosing too high could cause side effects, dosing too low doesn’t bring relief.
Every new batch of allergy pills starts with testing. Scientists use a tiny sample of the reference standard to confirm what they have made contains exactly what it’s supposed to. This comparison protects public health. Authorities like the FDA check medicines this way during approval, and later on when testing random samples from store shelves. Without a reliable standard, this oversight falls apart.
The reference standard also plays a role in research and clinical studies. Researchers exploring new ways to deliver fexofenadine—such as extended-release tablets or child-friendly syrups—run tests against this standard. If hospitals or doctors suspect a bad batch, comparison to the reference standard helps spot the problem before widespread harm occurs.
It sounds simple: just use the reference standard. Real-world practice complicates things. Reference standards must stay pure, be traceable, and get stored under strict conditions. Degraded or contaminated standards lead to mistakes that doctors and patients cannot afford. Manufacturers need robust systems for storage and handling. Routine checks for quality, temperature logs, and tamper seals may avoid failures in testing or mislabeling down the line.
Collaboration offers another solution. Pharmacopeias, such as the United States Pharmacopeia (USP), supply vetted standards, taking pressure off individual labs. Clear communication between drug makers, regulatory agencies, and scientists builds trust—you know the tablet in your pocket is safe because the test sticks to the reference standard. If supply shortages hit, fast track sharing and verified sourcing can keep the pipeline safe for patients reliant on day-to-day allergy relief.
Behind every allergy pill, there’s a network of people ensuring every dose lives up to its promise. Reference standards keep the system honest and doctors confident. Patients and pharmacists alike deserve that peace of mind each time they count on their medicine to work the way it should.
Every time I hear about proper storage for pharmaceutical reference standards, I remember the day I walked into a lab and saw a faded label on a tiny glass vial. Someone left it on a countertop under the sunlight, hoping to return after lunch. By afternoon, the compound inside had lost its usual color. No one could trust its quality anymore, yet this was a batch that once drove entire validation exercises. That little vial taught me a lesson in the real cost of messing up storage for chemical standards like Fexofenadine Hydrochloride.
Reference standards don’t come cheap or easy, since labs rely on them to check the accuracy and reliability of their results. Pharmaceutical regulators—and anyone in the quality business—want scientific results that stand up to scrutiny. Stability gets lost in the shuffle if teams treat these substances like any other bottle on the shelf. With Fexofenadine Hydrochloride, stability means everything. Poorly stored powder brings guesswork to every assay, and that trickles down, affecting safety and public trust.
Cold storage belongs at the top of the checklist. Fexofenadine Hydrochloride tends to hold up well at 2–8°C, tucked into a sealed glass container away from the reach of freeze-thaw cycles. Frost-free home refrigerators won’t do; temperature must stay steady. Any swinging up or down can open the door to physical or chemical changes inside the vial.
The bottle deserves a spot away from strong light. UV rays break down sensitive molecules. A dark amber glass bottle or a storage drawer without a window finish the job far better than clear plastic.
Moisture always looks for a way in, especially in humid climates or busy labs. Some folks wrap vials in parafilm, but I’ve found that tight screw caps with an inner seal cut down most exposure. When reference standards start caking or clumping, that’s usually water at work. Even just a small amount can change not only the weight, but also how much of the compound dissolves during prep work. Labs lose trust in their own controls once this happens.
People tend to overlook the small mistakes—leaving bottles open too long, switching containers, or sharing scoops between samples. I saw one instance where a "borrowed" spatula mixed traces of another standard right into a Fexofenadine standard. I’ve found that labeling everything with batch number, date of receipt, and opening date keeps things honest and easy to track. Knowing exactly how long an open reference standard sat on a bench or in transit can prevent costly reruns later on.
Check certificates of analysis for precise manufacturer guidelines. Still, those printed words only do so much. Practical storage practices—cool, dry, dark, and with serious attention given to minimizing human error—give any reference standard its best shot at performing as intended. I recall a senior analyst who taped a list on the fridge: "Don’t store food, don’t overload, check the thermometer daily." Simple advice, but it stopped a world of problems before they started. Routine checks and careful habits keep labs ahead of surprises.
Anyone checking laboratory shelves for drugs like fexofenadine hydrochloride knows right away: if the reference standard isn’t pure, not much else will matter in quality testing. The role of a reference standard is straightforward: confirm a drug's identity, strength, and quality. Analysts rely on these standards each day, trusting the purity so that every dose is right for the people needing relief from allergies. No room for shortcuts.
The pure standard, as found in many pharmacopoeias such as the USP (United States Pharmacopeia) or EP (European Pharmacopoeia), usually reads above 99%. These bodies run intense checks — NMR, HPLC, melting point, even mass spectrometry. Chemical labels do more than just sit on a shelf; they carry the hopes of patients, the responsibility of pharmacists, and the trust that doctors put in the supply chain. Over the years, I’ve seen analysts double-check the batch, running multiple assays and always raising an eyebrow if the number dips, even a fraction below. You build habits around these checks, almost like muscle memory, after seeing what happens with a tainted batch.
Pharmaceutical companies invest heavily in these test samples. Their reputation, legal standing, and the safety of patients depend on that little bottle. Regulatory guidelines require analytical work to use a reference standard that exceeds 99% purity. A standard at this level ensures every comparison is fair, making each test robust. The best labs keep reference standards dry, dark, and away from heat. Microdegradation might seem small, but even slight contamination can change results.
Fexofenadine hydrochloride, as supplied from reputable sources like the USP, typically ranges from 99.0% to 100.5%. These numbers might sound trivial, but think back to school science fairs — a drop too much or a dash of mystery dust, and the whole experiment goes sideways. Now imagine that experiment controls what’s inside every allergy tablet someone swallows in springtime. My own lab days showed me what happens when purity slips — inconclusive data, failed stability batches, and at worst, medicine recalls that cost millions and shake public trust.
Testing methods aren’t some black box magic. HPLC (High Performance Liquid Chromatography) stands as the workhorse. The process sorts molecules and checks for anything out of place. NMR (Nuclear Magnetic Resonance) tells chemists if the structure fits, down to the last hydrogen. Some methods catch tiny degradants down to parts-per-million. If there’s ever a question about a lot or a shipment, secondary checks run immediately—no waiting around. Regulators do random sampling, reviewing certificates of analysis, verifying storage, and even testing the containers for accidental leaks or light damage.
Problems can crop up, of course. Delays at shipping points raise suspicions about melting or moisture getting in. Long-term storage brings its own issues; standards have expiry dates for good reason. It’s tempting to cut corners, especially on costs, but if a pharmacist calls you about odd test results or failed system suitability, you end up spending far more chasing the problem than you save on a bottle.
Getting the most out of a standard means starting with trusted suppliers, ideally certified and recognized by global health bodies. Regular audits of storage, frequent retesting, and updating reference material as new impurities are discovered keeps everyone honest. In my own experience, sharing data and observations between labs helped catch inconsistencies early. Pharmacies and testing facilities must train staff to spot issues quickly. Even simple best practices — gloves, sealed bottles, silicate packs — play a role.
Building strong communication across labs, regulators, and suppliers means catching problems before they push into production. The purity of the fexofenadine hydrochloride reference standard isn’t just a number on a label. It’s patient trust, safe medicines, and science working exactly the way we hope it will.
In the world of pharmaceuticals, trust often comes down to traceability and proof. Fexofenadine Hydrochloride, the antihistamine behind countless allergy medications, gets scrutinized more than most active ingredients. Research teams and quality control labs rely on reference standards to verify their own test results. Without a Certificate of Analysis (CoA), the reference standard loses much of its value. A CoA does far more than pile on paperwork—it acts as a handshake and a promise between seller and user. Having spent hours in quality control labs, I can recall the scramble when a shipment arrived without a proper certificate. Work grinds to a halt until that sheet shows up.
Each CoA includes specifics that can’t be overlooked. Key data like assay test results, trace moisture content, identification tests, and expiry dates give us a fair measure of what’s actually in the vial. Suppliers like the United States Pharmacopeia (USP) and the European Pharmacopeia don’t cut corners here. Every batch gets a unique identifier, and the CoA ties test results to that lot. Research scientists depend on these details to avoid false positives or running expensive stability tests with a subpar batch.
No reputable provider skips the CoA step when shipping Fexofenadine Hydrochloride reference standards. International guidelines from bodies like the FDA and ICH set high expectations. Regulations demand batch-specific certificates accompanied by full test results, traceability records, and signatures from authorized analysts. During audits, inspectors want to see traceable proof bridging the reference standard and the analytical results in the lab. Without a valid certificate, data can get thrown out—something I’ve seen happen to months of work in backlogged regulatory reviews. Having clear labeling, full documentation, and transparency isn’t a luxury—it's a necessity to stay compliant with safety and efficacy standards.
Choosing a reference standard supplier often hinges on their willingness to communicate and provide proper documentation. Direct conversations with their technical team should quickly answer whether the CoA will be included and if it covers all necessary tests. Some smaller suppliers cut corners to trim costs. The buyer—often a junior analyst tasked with procurement—pays the price in lost time and reputational risk. Years of audit experience taught me that skimping on CoA verification can come back during inspections, creating costly lessons.
More suppliers are moving their documentation online. Secure, web-based certificate access streamlines traceability for labs juggling dozens of substances. Digital signatures and QR codes speed up verification. While technology helps, the basics remain: batch-specific, up-to-date data sent with every reference standard. Training procurement teams to ask for (and check) the CoA on every shipment matters as much as any fancy new portal. Gaps still appear with new or unregulated suppliers, so industry groups and associations should keep pushing for tighter industry-wide standards and clear consequences for lapses. Building a habit of double-checking certificates might seem simple—until the day you’re missing one and your work gets stuck on hold.
Anyone who’s ever cracked open a vial of Fexofenadine Hydrochloride reference standard knows the process calls for both patience and precision. Reference standards don’t just serve as lab inventory – they set the baseline for all analytical testing. If they’re not stored or handled right, the whole chain of analysis risks falling apart. In my years working alongside quality control teams, I’ve watched great labs lose valuable data because they skipped a basic step in handling or forgot about the simple hazards lurking in lapses.
Fexofenadine Hydrochloride won’t tolerate lazy storage. It handles best in a dry, cool spot away from direct sunlight. High humidity can trigger clumping or even compromise potency due to unwanted physical or chemical changes. Keeping the standard under desiccation, preferably with a working desiccator and silica gel, makes a difference. Most good labs run their refrigerators at 2–8°C—not just to check a box, but because failing to do so has led to expensive replacement of spoiled reference material.
Sunlight and bright lab lights trigger degradation. I’ve seen teams store reference standards in amber vials or, even better, in opaque secondary containers. Simple habits like labeling vials right, using tamper-evident seals, and wiping down all work benches stop accidental contamination, which can sneak in through something as simple as a forgotten pen mark or a smudged glove.
Every bottle’s arrival starts with verification: matching the certificate of analysis with the physical container, noting batch, expiry date, and manufacturer. No one appreciates tedious record-keeping until a regulatory inspection calls for traceability. I still remember a friend’s team stumbling because a single batch transfer lacked a proper date. They fixed the process by typing log sheets into digital spreadsheets, adding barcoding for each new shipment. This lets you track every usage and go back for root cause analysis if anything drifts in assay results.
Once the bottle’s open, minimizing its exposure to air prevents oxidation and water uptake. I use calibrated micro-spatulas because even a couple extra milligrams drawn by accident can skew results or introduce who-knows-what from careless tools. Sampling always happens in a dedicated weighing room—less dust, less vapor, less risk. If any dust or residue lands in the bottle, potency might slip. Experienced analysts always close every vial immediately, logging the adjusted weight right away.
Expired reference standard doesn’t belong on a shelf “just in case.” Once a batch hits its expiry, I send it for chemical waste disposal as per local environmental rules. Wearing gloves, goggles, and a lab coat stays standard. Even though Fexofenadine isn't the harshest compound, always anticipate accidental spills; I recommend keeping spill kits visible nearby and teaching newcomers that even a tiny exposure deserves cleanup, not a shrug.
Better habits around storage, handling, and documentation stop expensive mistakes before they start. Regulatory folks and auditors notice clean, organized environments and precise logs. I have watched labs move from chaos to consistency—better-trained teams, less waste, and consistently accurate results for assays, calibration, and quality control. Every gram of Fexofenadine Hydrochloride reference standard is expensive; treating it with respect pays off long before the final report leaves your desk.
| Names | |
| Preferred IUPAC name | 2-[4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid hydrochloride |
| Other names |
Fexofenadine HCl Fexofenadine Hydrochloride Allegra Reference Standard Fexofenadine Hydrochloride USP Reference Standard |
| Pronunciation | /ˌfɛksəˈfɛnədiːn haɪˌdrɒklaɪˈraɪd ˈrɛfərəns ˈstændərd/ |
| Identifiers | |
| CAS Number | 153439-40-8 |
| Beilstein Reference | Beilstein Reference: 6093654 |
| ChEBI | CHEBI:131021 |
| ChEMBL | CHEMBL1201303 |
| ChemSpider | 21543977 |
| DrugBank | DB00950 |
| ECHA InfoCard | 03e9cf42-6611-4b56-b8c0-8aa17814b55e |
| EC Number | 602-196-5 |
| Gmelin Reference | 13716454 |
| KEGG | D08102 |
| MeSH | D017209 |
| PubChem CID | 123620 |
| RTECS number | DY5950400 |
| UNII | K8RIT8BOKV |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C32H39NO4·HCl |
| Molar mass | 502.94 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | Density: 1.2 g/cm3 |
| Solubility in water | Freely soluble in water |
| log P | 1.52 |
| Acidity (pKa) | 4.25 |
| Basicity (pKb) | 9.35 |
| Dipole moment | 4.98 D |
| Pharmacology | |
| ATC code | R06AX26 |
| Hazards | |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS07, Warning, H315, H319, H335 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep container tightly closed. Store in a dry, cool and well-ventilated place. Wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). |
| Flash point | > 242.7 °C |
| Lethal dose or concentration | Lethal dose or concentration: LD₅₀ (oral, rat): > 2000 mg/kg |
| LD50 (median dose) | > 4047 mg/kg (Rat, oral) |
| NIOSH | 800034 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 1 year |
| Related compounds | |
| Related compounds |
Fexofenadine Terfenadine Desloratadine Loratadine |
